172
Participants
Start Date
December 31, 2005
Primary Completion Date
January 31, 2009
Study Completion Date
January 31, 2009
HKI-272
320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
Memorial Sloan-Kettering, New York
Carolinas Hematology-Oncology Associates, Charlotte
Case Western Reserve University, Cleveland
Cleveland Clinic, Cleveland
University of Minnesota, Minneapolis
Midwestern Regional Medical Center, Zion
USC Norris Comprehensive Cancer Center, Los Angeles
Institut Gustave Roussy, Villejuif
Swedish Cancer Institute, Seattle
Seattle Cancer Care Alliance, Seattle
Massachusetts General Hospital, Yawkey Center for Outpatient Care, Boston
Vanderbilt University Medical Center, Nashville
Országos Korányi TBC és Pulmonológiai Intézet, Budapest
University of Debrecen, Debrecen
Akademia Medyczna W Gdansku, Gdansk
Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock
Wielkopolskie Centrum Chorób Płuc i Gruźlicy, Poznan
Dolnośląskie Centrum Chorób Płuc we Wrocławiu, Wroclaw
Hospital Germans Trias I Puyol, Badalona
Puma Biotechnology, Inc.
INDUSTRY